Skip to main content

SciSparc Ltd.

corporate_fare Company Profile

SciSparc Ltd.

SPRC·NASDAQ·Life Sciences·CIK 0001611746

SciSparc Ltd. is a clinical-stage pharmaceutical company that develops drugs based on cannabinoid therapies. Its drug development programs include SCI-110, which is being developed for the treatment of Tourette syndrome and Alzheimer's disease and agitation. Another program, SCI-210, targets autism spectrum disorder and status epilepticus. The company also develops CannAmide, an anti-inflammatory and chronic pain solution. In addition to its drug development, SciSparc Ltd. sells hemp seed oil-based products and other related items. The company has an agreement with Procaps for the development and commercial manufacturing of SCI-110, palmitoylethanolamide oral tablets, and CannAmide in softgel capsule form. SciSparc Ltd. also has an agreement with The Israeli Medical Center for Alzheimer's to conduct a phase IIa clinical trial. This trial evaluates the safety, tolerability, and efficacy of SCI-110 in patients with Alzheimer's disease and agitation. Furthermore, the company has a collaboration with Clearmind Medicine Inc. SciSparc Ltd. was incorporated in 2004 and is headquartered in Tel Aviv-Yafo, Israel. The company was formerly known as Therapix Biosciences Ltd. and changed its name to SciSparc Ltd. in January 2021.

SciSparc Ltd. (NASDAQ:SPRC) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 31 items for SPRC at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-10-26, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 6 rated 8 or above. Recent SEC coverage for SPRC spans 6-K, F-3/A, 144, 20-F.

Recent high-impact activity:

  • SciSparc Cuts L.I.A Pure Capital Warrant Strike to $1.00, Raising $405,728
  • SciSparc Converts $2.02M Note at $1.50, Issuing ~1.35M Shares With No Cash Proceeds
  • SciSparc Flags Going Concern Doubt as Cash Runs Short
  • SciSparc's NeuroThera Expands U.S. Patent Portfolio with LSD, Ketamine, and Ibogaine Combinations
  • SciSparc-Clearmind MDMA-PEA Patent Published as FDA Finalizes Psychedelic Guidance

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$856K
Net Income
-$12.56M
Diluted EPS
$98.07
Op. Cash Flow
-$4.14M
Gross Profit
$631K
Operating Income
-$8.37M
Cash & Equivalents
$4.59M
Total Debt
$356K
Debt / Equity
0.07×
Net Margin
-14.68×
Shares Outstanding
365.44K sh
Source: 20-F · filed 2026-08-19 · accession 0001213900-26-091427

Short Interest & Short Volume

1.00 days to cover

FINRA reported short interest of 12,131 shares in SPRC as of the October 15, 2026 settlement, a 6.7% increase from the prior period — about 1.0 days to cover at its recent average daily volume. On October 29, 2026, 54.5% of SPRC volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)12,131 shares as of October 15, 2026
Change vs prior period▲ 6.7%
Days to cover1.00 at avg daily volume of 3,089,691
Daily short volume (FINRA facilities)54.5% of 245,163 shares on October 29, 2026
5-day average short volume59.0%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Dilution Risk

Low risk

Filing-implied dilution signals for SPRC, detected from its recent SEC filings · based on capital-structure filings through 2026-10-26.

1 shelf registration

Warrant Strike Cut to $1.00 · About $405,728 in Gross Proceeds

A filing-implied signal, not a realized share count. How Wiseek tracks dilution →

Insider Transactions

SPRC files as a Foreign Private Issuer (FPI). Under SEC Exchange Act Section 16(a), officers, directors, and 10% owners of FPIs are exempt from Form 4 insider-transaction reporting requirements. Comparable disclosures, when applicable, appear in the company's Form 20-F (annual) or Form 6-K (interim) filings on SEC EDGAR.

Browse all tickers starting with S →
$0.632 -11.27% today
52-week range · as of 2026-10-26 $0.632 – $37.9
Market cap
$1.3M
Volume
279.4K (0.1× avg)
3-mo avg 2.8M
Live data · 2026-10-30 17:10 UTC · Market open

show_chartPrice Chart

Loading chart...

feed SPRC - Latest Insights

SPRC
Oct 26, 2026, 4:01 PM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $1.28
Real-time Price: $0.632 info
Change: -$0.648 (-51%) info
Market Cap: $1.3M info
SPRC
Oct 15, 2026, 1:30 PM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $4.31
Real-time Price: $0.632 info
Change: -$3.68 (-85%) info
Market Cap: $1.3M info
SPRC
Sep 30, 2026, 5:05 PM EDT
Filing Type: 6-K
Importance Score:
9
Price at Filing: $4.72
Real-time Price: $0.632 info
Change: -$4.09 (-87%) info
Market Cap: $1.3M info
SPRC
Sep 23, 2026, 8:35 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $4.64
Real-time Price: $0.632 info
Change: -$4.01 (-86%) info
Market Cap: $1.3M info
SPRC
Aug 24, 2026, 8:51 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $7.30
Real-time Price: $0.632 info
Change: -$6.66 (-91%) info
Market Cap: $1.3M info
SPRC
Aug 19, 2026, 4:01 PM EDT
Filing Type: F-3/A
Importance Score:
7
Price at Filing: $6.86
Real-time Price: $0.632 info
Change: -$6.23 (-91%) info
Market Cap: $1.3M info
SPRC
Aug 18, 2026, 4:02 PM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $6.51
Real-time Price: $0.632 info
Change: -$5.88 (-90%) info
Market Cap: $1.3M info
SPRC
Aug 05, 2026, 8:22 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $7.96
Real-time Price: $0.632 info
Change: -$7.33 (-92%) info
Market Cap: $1.3M info
SPRC
Jul 31, 2026, 8:20 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $7.71
Real-time Price: $0.632 info
Change: -$7.08 (-92%) info
Market Cap: $1.3M info
SPRC
Jul 15, 2026, 8:41 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $4.66
Real-time Price: $0.632 info
Change: -$4.03 (-86%) info
Market Cap: $1.3M info
SPRC
Jun 22, 2026, 1:46 PM EDT
Filing Type: 144
Importance Score:
7
Price at Filing: $6.93
Real-time Price: $0.632 info
Change: -$6.30 (-91%) info
Market Cap: $1.3M info
SPRC
Jun 03, 2026, 5:15 PM EDT
Source: TheNewswire
Importance Score:
7
Price at Filing: $9.45
Real-time Price: $0.632 info
Change: -$8.82 (-93%) info
Market Cap: $1.3M info
SPRC
May 29, 2026, 7:40 AM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $9.24
Real-time Price: $0.632 info
Change: -$8.61 (-93%) info
Market Cap: $1.3M info
SPRC
May 28, 2026, 8:40 AM EDT
Source: Dow Jones Newswires
Importance Score:
8
Price at Filing: $4.54
Real-time Price: $0.632 info
Change: -$3.91 (-86%) info
Market Cap: $1.3M info
SPRC
May 11, 2026, 8:00 AM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $6.20
Real-time Price: $0.632 info
Change: -$5.57 (-90%) info
Market Cap: $1.3M info
SPRC
Apr 29, 2026, 4:20 PM EDT
Filing Type: 20-F
Importance Score:
9
Price at Filing: $9.04
Real-time Price: $0.632 info
Change: -$8.41 (-93%) info
Market Cap: $1.3M info
SPRC
Mar 16, 2026, 8:21 AM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $4.33
Real-time Price: $0.632 info
Change: -$3.70 (-85%) info
Market Cap: $1.3M info
SPRC
Mar 12, 2026, 4:41 PM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $4.22
Real-time Price: $0.632 info
Change: -$3.59 (-85%) info
Market Cap: $1.3M info
SPRC
Mar 12, 2026, 7:55 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $4.56
Real-time Price: $0.632 info
Change: -$3.93 (-86%) info
Market Cap: $1.3M info
SPRC
Mar 10, 2026, 9:28 AM EDT
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $4.78
Real-time Price: $0.632 info
Change: -$4.15 (-87%) info
Market Cap: $1.3M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets